|
DE69636170T2
(de)
*
|
1995-03-20 |
2006-11-02 |
Okumura, Ko |
Monoklonaler antikörper, der spezifisch mit dem fas-liganden reagiert, und verfahren zu seiner herstellung
|
|
AU6091496A
(en)
*
|
1995-06-07 |
1996-12-30 |
Chiron Corporation |
Antibodies to fas antigen capable of inhibiting apoptosis
|
|
US6096312A
(en)
*
|
1995-06-30 |
2000-08-01 |
Mochida Pharmaceutical Co., Ltd. |
Agent for suppressing a reduction of CD4+ lymphocytes
|
|
JPH09124509A
(ja)
*
|
1995-10-27 |
1997-05-13 |
Sumitomo Electric Ind Ltd |
肝炎治療剤
|
|
DE19544333C2
(de)
*
|
1995-11-28 |
1998-12-10 |
Deutsches Krebsforsch |
Verfahren zur Beurteilung der Aktivität von Arzneistoffen
|
|
AU2814897A
(en)
*
|
1996-04-25 |
1997-11-12 |
T Cell Sciences, Inc. |
Method of isolating regulators of t cell activation
|
|
GB9703276D0
(en)
*
|
1997-02-17 |
1997-04-09 |
Screaton Gavin R |
Materials and methods relating to the protection of useful immune cells
|
|
AU1288099A
(en)
*
|
1997-10-30 |
1999-05-24 |
Cornell Research Foundation Inc. |
A method of inhibiting an immune response to a recombinant vector
|
|
EP1447093A1
(en)
*
|
2003-02-14 |
2004-08-18 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
|
|
JP2007533595A
(ja)
*
|
2003-03-26 |
2007-11-22 |
アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ウィルス感染の治療
|
|
DK2101877T3
(da)
|
2006-12-28 |
2013-09-23 |
Deutsches Krebsforsch |
Neutralisering af virkningen af CD95 til blokering af invasion af glioblastomceller in vivo
|
|
WO2010003766A2
(en)
|
2008-06-17 |
2010-01-14 |
Apogenix Gmbh |
Multimeric tnf receptors
|
|
EP2456468A1
(en)
*
|
2009-07-21 |
2012-05-30 |
Queen Mary and Westfield College |
Fas (apo-1, cd95) targeted platforms for intracellular drug delivery
|
|
JP6297552B2
(ja)
|
2012-07-18 |
2018-03-20 |
アポジェニックス アーゲー |
Ｍｄｓの治療のための、ｃｄ９５シグナル伝達経路阻害剤
|
|
EP3076179A1
(en)
|
2015-03-30 |
2016-10-05 |
Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts |
Diagnosis and treatment of low grade gliomas
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
CN110462027A
(zh)
|
2017-01-06 |
2019-11-15 |
艾欧凡斯生物治疗公司 |
用肿瘤坏死因子受体超家族（tnfrsf）激动剂扩增肿瘤浸润淋巴细胞（til）及til和tnfrsf激动剂的治疗组合
|
|
CA3049165A1
(en)
|
2017-01-06 |
2018-07-12 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
|
IL270412B2
(en)
|
2017-05-10 |
2025-03-01 |
Iovance Biotherapeutics Inc |
Expansion of infiltrating lymphocytes from liquid samples and their medical uses
|
|
EP3714041A1
(en)
|
2017-11-22 |
2020-09-30 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
|
WO2019118873A2
(en)
|
2017-12-15 |
2019-06-20 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
|
EP3752600A1
(en)
|
2018-02-13 |
2020-12-23 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
|
|
MX2021010288A
(es)
|
2019-03-01 |
2021-09-23 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes de tumores a partir de tumores liquidos y usos terapeuticos de los mismos.
|
|
EP3946437B1
(en)
|
2019-03-29 |
2025-11-19 |
H. Lee Moffitt Cancer Center and Research Institute, Inc. |
Ex vivo methods for producing a t cell therapeutic and related compositions and methods
|
|
CN115023270A
(zh)
|
2019-11-27 |
2022-09-06 |
迈斯特治疗公司 |
使用调节剂产生肿瘤反应性t细胞组合物的方法
|
|
IL295990A
(en)
|
2020-02-27 |
2022-11-01 |
Myst Therapeutics Llc |
Methods for in vitro enrichment and expansion of tumor-reactive t cells and preparations related thereto
|
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|